Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
  • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
  • C07D495/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
  • C07D209/04—Indoles; Hydrogenated indoles
  • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring

Definitions

• the present invention relates to novel tetrahydrothiopyrano[3,2-b]indole derivatives and pharmaceutically acceptable salts thereof and to a process for the preparation thereof.
• tetrahydrothiopyrano[3,2-b]indole derivatives and their pharmaceutically acceptable salts are useful medicaments exhibiting analgesic, anti-inflammatory and anti-depressant activities.
• This invention provides a compound of the formula [I]: wherein
• C 1-6 alkyl refers to straight, branched and cyclic aliphatic radicals having from one to six carbon atoms including, e.g. methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, cyclopropyl, cyclobutyl, cyclohexyl, and cyclopropylmethyl.
• C 2-6 alkenyl refers to a group having one or more double bonds in the above straight or branched alkyl chain, e.g. vinyl, allyl, butenyl, isobutenyl, pentenyl and isopentenyl.
• C 2-6 alkynyl refers to a group having one or more triple bonds in the above straight or branched alkyl chain including e.g. ethynyl, 1-propynyl, 2-propynyl, 2-butynyl and 4-pentynyl.
• the substituents on the phenyl include such as C 1-4 alkyl (e.g. methyl, ethyl, propyl, isopropyl, butyl), C 1-4 alkoxy (e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy), halogen (e.g. chlorine, bromine, iodine) and hydroxy.
• R 6 CO includes e.g. acetyl, propionyl, butyryl, isobutyryl, valeryl, benzoyl and substituted benzoyl (e.g. P-C 1-4 alkylbenzoyl, P-C 1-4 alkoxybenzyl and p-halogenobenzoyl).
• the group includes aminoalkyl, C 1-6 alkylaminoalkyl, N,N-di-C 1-6 alkylaminoalkyl and their oxo-substituted equivalents (e.g. aminomethyl, methylaminomethyl, methylaminoethyl, ethylaminopropyl, N,N-dimethylaminomethyl, N,N-diethylaminoethyl, N,N-dimethylaminopropyl, carbamoyl, N-methylaminoacetyl, 3-(N,N-dimethylamino)-2-oxo-propyl).
• aminoalkyl C 1-6 alkylaminoalkyl
• N,N-di-C 1-6 alkylaminoalkyl and their oxo-substituted equivalents (e.g. aminomethyl, methylaminomethyl, methylaminoethyl, ethylaminopropy
• the compounds of this invention include 4-(substituted or unsubstituted-amino)methyl-2,3,4,5-tetrahydrothiopyrano[3,2-b]indoles optionally having substituents at the 4 and/or 5 position, and the sulfur atom at the 1 position may be oxide or dioxide
• this invention includes the pharmaceutically acceptable salts of Compound [I], for example, hydrochloride, hydrobromide, hydroiodide, sulfate, phosphate, methanesulfonate, acetate, citrate, oxalate, fumarate, malate, succinate, maleate, phthalate, cinnamate, benzoate and ascorbate.
• FR-A-2 426 689 discloses derivatives of tetrahydrothiopyrano-[2,3-b]-indole having analgesic and anti-inflammatory properties.
• GB-A-1 391 234 discloses tetrahydrothiopyrano-[4,3-b]-indoles which have anti-depressant activities.
• Compound [I] is novel. Any compound having 2,3,4,5-tetrahydrothiopyrano[3,2-b]indole nucleus has not yet been known. Naturally, it is not known that Compound [I] has analgesic, anti-inflammatory and/or anti-depressant activity.
• Compound [I] can be prepared by various methods, one of which is illustrated as follows: - (wherein R 1 , R 2 , R 3 , R 4 and n each is as defined above).
• Thiol derivative [IV] is prepared by Harris's method: Tetrahefron Letters, 1969, 4465. Namely, indole or 1-substituted indole is treated with thiourea in the presence of iodine-potassium iodide and the resulting isothiuronium salt is hydrolyzed by alkaline. Besides, 3-indolylthiol has been prepared by Harris and 1-methyl-3-indolylthiol by Marches: Chim. Ind. (Milan.), 51, 41 (1969).
• Compound [III] is prepared by reacting Compound [IV] with 4-halogeno-2-butyn-1-ol in the presence of a dehydrohalogenating agent. The reaction is carried out in an inert organic solvent at room temperature or under heating.
• Compound [II] can be prepared by cyclizing Compound [III] under heating.
• the reaction is carried out in an inert organic solvent (e.g. benzene, toluene, xylene, dimethylformamide, dimethylsulfoxide, alcohols, pyridine and dimethylaniline).
• an inert organic solvent e.g. benzene, toluene, xylene, dimethylformamide, dimethylsulfoxide, alcohols, pyridine and dimethylaniline.
• the formyl group at the 4 position of Compound [II] can be converted into aminomethyl, for example, by reacting Compound [II] with ammonia or a primary or secondary amine under reductive condition or followed by reduction, if necessary.
• the reaction of Compound [II] and an amine is carried out in an inert organic solvent, e.g. benzene, or alcohols, at room temperature or under heating.
• the resultant Schiff base is treated with a reducing agent such as metal hydride, sodium-alcohol or formic acid.
• Formic acid is preferably used when a secondary amine is reacted.
• the reduction can be performed without isolation of the resultant Schiff base.
• the reaction of Compound [II] can be effected with an amine under reductive condition, namely in the presence of a suitable reducing agent to give the desired Compound [I].
• Alkylation of Compound [I] of which R 4 is hydrogen is effected in a usual manner and gives the aimed Compound [I] of which R 4 is not hydrogen.
• an alkylation by using an alkali metal compound (e.g. sodium hydride, potassium hydroxide) and alkyl halide (e.g. methyl iodide) in an inert organic solvent (e.g. dimethylformamide, dioxane, dimethylsulfoxide).
• an alkali metal compound e.g. sodium hydride, potassium hydroxide
• alkyl halide e.g. methyl iodide
• an inert organic solvent e.g. dimethylformamide, dioxane, dimethylsulfoxide
• R 1 can be introduced to Compound [I] of which R 1 is hydrogen in the same manner as in the above b. Further, R 1 can be replaced by another desired R 1 by removing the former R 1 in a conventional manner followed by introducing the other substituent R 1.
• Oxidation of the sulfur atom at the 1 position can be carried out by a conventional method.
• the reaction is carried out with a usually utilized peracid (e.g. perchloric acid, periodic acid, perbenzoic acid, m-chloroperbenzoic acid) in an inert organic solvent at room temperature or under heating.
• a usually utilized peracid e.g. perchloric acid, periodic acid, perbenzoic acid, m-chloroperbenzoic acid
• the product may be converted into the desired salt.
• the salt formation can be carried out in a conventional manner.
• a reactive substituent of Compounds [I] and [II] may be protected at any step in the above steps a to e, if necessary, and the protecting group may be removed at a suitable step if required.
• a 0.9% saline solution (0.05 ml) containing 1.0% carrageenin is used as phlogistic agent.
• JCL-Wistar female rats (180-200 g body weight) are orally administered a test compound, and the phlogistic agent is injected subcutaneously into the plantar of the feet of the rats.
• the volume of swelling is measured 3 hours later and the anti-edema activity is determined by calculating a ratio (%) of the edematous volume of medicated foot to that of non-medicated foot.
• mice (20-23 g, body weight) are treated with an intraperitoneal injection of 0.1 ml/10 g of 0.6% acetic acid 30 minutes after oral administration of a test compound. The number of writhing times for 10 minutes is counted and ED 50 is calculated.
• mice (20-23 g, male) are orally administered a suspension of test compound with gum arabic. The mortality at the 72nd hour is determined and the LD 50 is calculated.
• the above tested compounds have analgesic and anti-inflammatory _ activities.
• the analgesic activity is much stronger than commercially available analgesic, aminopyrine.
• the other Compound [I] of this invention has nearly the same activities.
• Compound [I] has anti-depressant activity.
• Compound [I] can be used as analgesic, anti-inflammatory or anti-depressant agent.
• Compound [I] and its pharmaceutically acceptable salts can be applied to treatment of various pains of human beings and animals.
• the compounds of this invention can be administered alone or in combination with pharmaceutically acceptable carriers and other drugs, if necessary, orally, percutaneously or by injection.
• the compounds are used in combination with one or more carriers suited to the particular route of administration.
• carriers for internal or external use are lactose, sucrose, starch, dextrin, sodium bicarbonate, licorice powder, talc, kaoline, bentonite, calcium carbonate and paraffin and as gel or liquid carrier, gelatine, water, ethanol, isopropanol, chloroform and glycerol, are exemplified.
• Suitable forms of pharmaceutical preparation of Compound [I] are tablets, capsules, pills, ointments, granules, powders, suppositories, aerosols and injectable solutions.
• the invention also provides a therapeutic formulation which comprises 1 mg to 500 mg of one or more Compound [I] with or without a pharmaceutically acceptable carrier.
• Compound [I] is generally administered to human adults about 3 to about 500 mg a day, though the amount may largely be varied depending on conditions, e.g. case history, age and sex of the patient, administration route.
• the compound can be administered to human being either in a single or divided doses.
• the compound may also be administered at once for acute diseases.
• the invention includes a method for giving analgesic effect to an animal, which method comprises administering an effective amount of a Compound [I] to the animal according to this invention.
• a solution of 1-ethylindole (25 g) and thiourea (15.7 g) in methanol (400 ml) is mixed with an aqueous solution (250 ml) of potassium iodide (34.4 g) and iodine (26.3 g) and allowed to stand at room temperature for 2 hours.
• the mixture is stirred for 1 hour and condensed to give S-(1-ethyl-2- indolyl)isothiuronium iodide: mp. 225.5-228°C (decomp.).
• To the product is added 5% aqueous sodium hydroxide solution (200 ml).
• Liquid ammonia (ca. 100 ml) is trapped in a solution of 4-methylaminomethyl-5-benzyl-2,3,4,5-tetrahydrothiopyrano[3,2-b]indole (1.6 g) in ether (20 ml) under cooling at -70°C. A piece of sodium metal is added occasionally under refluxing. The refluxing is continued for 1.5 hours after the dark green color of the reaction mixture disappears. The reaction mixture is neutralized with ammonium chloride, the excess ammonia removed, and then the residue extracted with methylene chloride after addition of water. The extract is washed with water, dried and evaporated to give the title compound (1.06 g): Yield 91.4%. Recrystallization from benzene-petroleum benzine gives crystals melting at 100-101 °C.
• a solution of 4-dimethylaminomethyl-2,3,4,5-tetrahydrothiopyrano[3,2-b]indole (1.00g) in dry dimethylformamide (25 ml) is mixed with 50% sodium hydride (293 mg) under stirring and the mixture is allowed to stand at 40°C for 1 hour. Then, the reaction mixture is mixed with a solution of isopropyl iodide (1.63 g) in dimethylformamide (2 ml) and kept at 40°C for 2 hours and further for 20 hours after addition of the reagent.
• the reaction mixture is mixed with ether and ice water successively at under 5°C. and the ether layer is separated. The aqueous layer is further extracted with ether.
• reaction mixture is washed with a sodium hydroxide aqueous solution and water, dried and evaporated to give 4-(N-methyl-N-t-butoxycarbonylaminomethyl)-5-methyl-2,3,4,5-tetrahydrothiopyrano[3,2-b]indole 1,1-dioxide.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Pain & Pain Management (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Rheumatology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Applications Claiming Priority (2)

Publications (2)

Family

ID=12119010

Family Applications (1)

Country Status (8)

Families Citing this family (3)

Citations (2)

• 1980
  • 1980-02-27 JP JP2375180A patent/JPS56120686A/ja active Granted
• 1981
  • 1981-01-19 CA CA000368802A patent/CA1158241A/en not_active Expired
  • 1981-01-30 ES ES498968A patent/ES8201134A1/es not_active Expired
  • 1981-02-25 DK DK085481A patent/DK150305C/da not_active IP Right Cessation
  • 1981-02-27 DE DE8181101451T patent/DE3162851D1/de not_active Expired
  • 1981-02-27 AU AU67934/81A patent/AU538185B2/en not_active Ceased
  • 1981-02-27 EP EP81101451A patent/EP0035259B1/en not_active Expired
  • 1981-06-11 ES ES502954A patent/ES502954A0/es active Granted
• 1984
  • 1984-07-25 US US06/633,686 patent/US4910318A/en not_active Expired - Fee Related

Patent Citations (2)

Also Published As

Similar Documents

Legal Events